BMS/AbbVie Empliciti Leaps Ahead, Wins Fast FDA Nod
This article was originally published in Scrip
The FDA has been on a roll in granting early approvals of drugs to treat multiple myeloma – giving its nod to three new products in just the past couple of weeks well ahead of their Prescription Drug User Fee Act (PDUFA) goal dates, with Bristol-Myers Squibb Co.'s and AbbVie Inc.'s Empliciti (elotuzumab) being the latest.
You may also be interested in...
Immediate interaction with US FDA after stressful advisory committee facilitated accelerated approval in fourth-line myeloma, company says. Four different dosing regimens will be priced at $22,000 for four weeks.
Janssen’s multiple myeloma therapy, Darzalex, has won an additional US approval for use earlier in the treatment paradigm, building momentum for a product that has already got off to a strong start.
With Darzalex in the spotlight at the ASCO annual meeting, J&J highlights its comprehensive focus on trio of disease areas – hematology, prostate cancer and lung cancer.